In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes
Abstract
Summary: The in vitro antifungal activity of suramin and its combinations with fluvastatin was investigated in this study. Several species belonging to the class Zygomycetes are considered agents of opportunistic human or animal infections. In the present work, 15 fungal isolates representing eight clinically important genera (Absidia, Micromucor, Mortierella, Mucor, Rhizomucor, Rhizopus, Saksenaea and Syncephalastrum) were investigated. The efficiency with which fluvastatin inhibited growth in the presence of suramin (100 μg ml−1) was studied. The investigated compounds acted synergistically and additively on the growth when a strain was resistant to suramin and sensitive to fluvastatin; at the same time, antagonistic interactions were detected when strains were sensitive to both agents. In these cases, the growth inhibition effect of suramin was dominant.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An antifungal peptide secreted by Penicillium chrsyogenum (PAF) and suramin can decrease growth of zygomyceteous fungal species in the presence of different statins.
“An antifungal peptide secreted by Penicillium chrsyogenum (Penicillium chrsyogenum antifungal protein; PAF) and a hexasulfonated naphtylurea, suramin (originally applied as an agent for treatment of parasitic infections) can decrease the growth of zygomyceteous fungal species in the presence of different statins [34,35] .”
From Statins as antifungal agents (2011) · cites this paper as [35]
Interactions were not detected between FLV and suramin if the strain was insensitive to both compounds, but synergistic and additive interactions were observed if the fungus was sensitive to FLV and insensitive to suramin; antagonistic interaction was observed if the fungus was sensitive to both drugs.
“Interactions were not detected between FLV and suramin if the investigated strain proved to be insensitive to both compounds, but synergistic and additive interactions could be observed if the fungus was sensitive to FLV and insensitive to suramin.Antagonistic interaction was observed if the fungus was sensitive to both drugs [35] .”
From Statins as antifungal agents (2011) · cites this paper as [35]
Drug interactions were revealed between statins and nonantifungal drugs that have secondary antifungal activity.
“Drug interactions were revealed between statins and nonantifungal drugs, which have a secondary antifungal activity.”
From Statins as antifungal agents (2011) · cites this paper as [35]
Cites
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994 · see citing works
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236-301.2000 · Cited by 1,315 · see citing works
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,109 · see citing works
Rex, J. H., & Clinical (2008) · Clinical and Laboratory Standards Institute eBooks · Cited by 695 · see citing works
The statins as anticancer agents.
Chan, K., Oza, A. M., & Siu, L. L. (2003) · PubMed · Cited by 607 · see citing works
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352 · see citing works
Mechanisms of Statin-mediated Inhibition of Small G-protein Function
Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., & Landreth, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505268200 · Cited by 235 · see citing works
Microbial natural products as a source of antifungals
Vicente, M. F., Basilio, Á., Cabello, A., & Peláez, F. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00489.x · Cited by 191 · see citing works
Ghittoni, R., Patrussi, L., Pirozzi, K., Pellegrini, M., Lazzerini, P. E., Capecchi, P. L., Pasini, F. L., & Baldari, C. T. (2005) · The FASEB Journal · doi:10.1096/fj.04-2702fje · Cited by 154 · see citing works
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.96-103.2006 · Cited by 121 · see citing works
Bapiro, T. E., Egnell, A., Hasler, J. A., et al. (2001) · PubMed · Cited by 118 · see citing works
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97 · see citing works
Lovastatin Triggers an Apoptosis-like Cell Death Process in the FungusMucor racemosus
Roze, L. V., & Linz, J. E. (1998) · Fungal Genetics and Biology · doi:10.1006/fgbi.1998.1093 · Cited by 96 · see citing works
Lipid signaling in pathogenic fungi
Shea, J. M., & Poeta, M. D. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.06.003 · Cited by 91 · see citing works
Drug interactions and the statins.
Herman, R. J. (1999) · Europe PMC (PubMed Central) · Cited by 86 · see citing works
Activity of the Antifungal Protein from Aspergillus giganteus Against Botrytis cinerea
Moreno, A. B., Martínez‐del‐Pozo, Á., Borja, M., & Segundo, B. S. (2003) · Phytopathology · doi:10.1094/phyto.2003.93.11.1344 · Cited by 82 · see citing works
Kontoyiannis, D. P. (2007) · Clinical Infectious Diseases · doi:10.1086/512817 · Cited by 69 · see citing works
Antifungal Activity of Nonantifungal Drugs
Afeltra, J., & Verweij, P. E. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0947-x · Cited by 63 · see citing works
Protein Kinase C (PkcA) of Aspergillus nidulans Is Involved in Penicillin Production
Herrmann, M., Spröte, P., & Brakhage, A. A. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.4.2957-2970.2006 · Cited by 55 · see citing works
Antifungal pharmacotherapy for invasive mould infections
Gallagher, J. C., Ashley, E. S. D., Drew, R. H., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.147 · Cited by 46 · see citing works
Differentiation of Rhizomucor Species on the Basis of Their Different Sensitivities to Lovastatin
Lukács, G., Papp, T., Nyilasi, I., Nagy, E., & Vágvölgyi, C. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.11.5400-5402.2004 · Cited by 40 · see citing works
Self-citationVillalona-Calero, M. A., Wientjes, M. G., Otterson, G. A., Kanter, S., Young, D. C., Murgo, A. J., Fischer, B., Dehoff, C., Chen, D., Yeh, T., et al. (2003) · PubMed · Cited by 39 · see citing works
Galgóczy, L., Papp, T., Lukács, G., Leiter, Ã., Pócsi, I., & Vágvölgyi, C. (2007) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2007.00661.x · Cited by 37 · see citing works
Self-citationGschwendt, M., Kittstein, W., & Johannes, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01530-5 · Cited by 36 · see citing works
Meletiadis, J., Dorsthorst, D. T. A. T., & Verweij, P. E. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.07.011 · Cited by 30 · see citing works
Hussain, M., Fisher, E. I., Petrylak, D. P., O’Connor, J., Wood, D. P., Small, E. J., Eisenberger, M. A., & Crawford, E. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1043 · Cited by 28 · see citing works
Combination Antifungal Therapy: The New Frontier
Vázquez, J. A. (2007) · Future Microbiology · doi:10.2217/17460913.2.2.115 · Cited by 21 · see citing works
Braga-Silva, L. A., dos Santos, A. L. S., Portela, M. B., Souto-Padrón, T. C. B. S., & Soares, R. M. D. A. (2007) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2007.00321.x · Cited by 17 · see citing works
Successful intraperitoneal suramin treatment of peritoneal mesothelioma
Westermann, A. M., Dubbelman, R., Moolenaar, W. H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008231901539 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73 · see citing works
Galgóczy, L., Lukács, G., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2010) · Acta Biologica Hungarica · doi:10.1556/abiol.61.2010.3.11 · Cited by 23 · see citing works
Self-citationAre Statins Applicable for the Prevention and Treatment of Zygomycosis?
Galgóczy, L., Nyilasi, I., Papp, T., & Vágvölgyi, C. (2009) · Clinical Infectious Diseases · doi:10.1086/600825 · Cited by 22 · see citing works
Self-citationGalgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21 · see citing works
Self-citationIs there a role for statins in fungal infections?
Bergman, P. W., & Björkhem-Bergman, L. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.856755 · Cited by 12 · see citing works
- Authors
- Galgóczy, L., Papp, T., & Vágvölgyi, C.
- Affiliations
- University of Szeged (HU)
- Corresponding author
- Galgóczy, László
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2009-07-29
- Volume
- 52
- Issue
- 5
- Pages
- 447-453
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1974626922
- Cited by
- 14
- References
- 29
- Citations by year
- 2025: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2015: 1 · 2013: 1
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Mycoses (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Magyar Tudományos Akadémia
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Veterinary › Small Animals › Infectious Diseases and Mycology
- Keywords
- suramin, fluvastatin, Zygomycetes, combination antifungal therapy, drug interactions, synergistic interaction, antagonism, Mucorales, opportunistic fungal infection, Mucor, Rhizopus, Syncephalastrum, drug resistance
- MeSH terms
- Fluvastatin, Animals, Antifungal Agents, Drug Interactions, Fatty Acids, Monounsaturated, Fungi, Humans, Indoles, Microbial Sensitivity Tests, Suramin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review